DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis

Abstract

Multiple sclerosis is an autoimmune neurodegenerative disease of the central nervous system characterized by pronounced inflammatory infiltrates entering the brain, spinal cord and optic nerve leading to demyelination. Focal demyelination is associated with relapsing-remitting multiple sclerosis, while progressive forms of the disease show axonal degeneration and neuronal loss. The tests currently used in the clinical diagnosis and management of multiple sclerosis have limitations due to specificity and sensitivity. MicroRNAs (miRNAs) are dysregulated in many diseases and disorders including demyelinating and neuroinflammatory diseases. A review of recent studies with the experimental autoimmune encephalomyelitis animal model (mostly female mice 6–12 weeks of age) has confirmed miRNAs as biomarkers of experimental autoimmune encephalomyelitis disease and importantly at the pre-onset (asymptomatic) stage when assessed in blood plasma and urine exosomes, and spinal cord tissue. The expression of certain miRNAs was also dysregulated at the onset and peak of disease in blood plasma and urine exosomes, brain and spinal cord tissue, and at the post-peak (chronic) stage of experimental autoimmune encephalomyelitis disease in spinal cord tissue. Therapies using miRNA mimics or inhibitors were found to delay the induction and alleviate the severity of experimental autoimmune encephalomyelitis disease. Interestingly, experimental autoimmune encephalomyelitis disease severity was reducedmore » by overexpression of miR-146a, miR-23b, miR-497, miR-26a, and miR-20b, or by suppression of miR-182, miR-181c, miR-223, miR-155, and miR873. Further studies are warranted on determining more fully miRNA profiles in blood plasma and urine exosomes of experimental autoimmune encephalomyelitis animals since they could serve as biomarkers of asymptomatic multiple sclerosis and disease course. Additionally, studies should be performed with male mice of a similar age, and with aged male and female mice.« less

Authors:
 [1];  [2]
  1. Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Chemistry Division. Physical Chemistry and Applied Spectroscopy; St. Georges Univ. (Grenada). School of Medicine. Dept. of Medicine
  2. Univ. of Otago, Dunedin (New Zealand). Dept. of Anatomy
Publication Date:
Research Org.:
Triad National Security, LLC, Los Alamos, NM (United States)
Sponsoring Org.:
USDOE Office of Science (SC)
OSTI Identifier:
1815782
Grant/Contract Number:  
89233218CNA000001
Resource Type:
Accepted Manuscript
Journal Name:
Neural Regeneration Research
Additional Journal Information:
Journal Volume: 15; Journal Issue: 10; Journal ID: ISSN 1673-5374
Publisher:
Chinese Association of Rehabilitation Medicine (CARM)
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; animal model; blood plasma; blood serum; brain tissue; disease biomarkers; experimental autoimmune; encephalomyelitis; microRNAs; multiple sclerosis; spinal cord; therapeutic targets; urine exosomes

Citation Formats

Martinez, Bridget, and Peplow, PhilipV. MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis. United States: N. p., 2020. Web. doi:10.4103/1673-5374.280307.
Martinez, Bridget, & Peplow, PhilipV. MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis. United States. https://doi.org/10.4103/1673-5374.280307
Martinez, Bridget, and Peplow, PhilipV. Fri . "MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis". United States. https://doi.org/10.4103/1673-5374.280307. https://www.osti.gov/servlets/purl/1815782.
@article{osti_1815782,
title = {MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis},
author = {Martinez, Bridget and Peplow, PhilipV},
abstractNote = {Multiple sclerosis is an autoimmune neurodegenerative disease of the central nervous system characterized by pronounced inflammatory infiltrates entering the brain, spinal cord and optic nerve leading to demyelination. Focal demyelination is associated with relapsing-remitting multiple sclerosis, while progressive forms of the disease show axonal degeneration and neuronal loss. The tests currently used in the clinical diagnosis and management of multiple sclerosis have limitations due to specificity and sensitivity. MicroRNAs (miRNAs) are dysregulated in many diseases and disorders including demyelinating and neuroinflammatory diseases. A review of recent studies with the experimental autoimmune encephalomyelitis animal model (mostly female mice 6–12 weeks of age) has confirmed miRNAs as biomarkers of experimental autoimmune encephalomyelitis disease and importantly at the pre-onset (asymptomatic) stage when assessed in blood plasma and urine exosomes, and spinal cord tissue. The expression of certain miRNAs was also dysregulated at the onset and peak of disease in blood plasma and urine exosomes, brain and spinal cord tissue, and at the post-peak (chronic) stage of experimental autoimmune encephalomyelitis disease in spinal cord tissue. Therapies using miRNA mimics or inhibitors were found to delay the induction and alleviate the severity of experimental autoimmune encephalomyelitis disease. Interestingly, experimental autoimmune encephalomyelitis disease severity was reduced by overexpression of miR-146a, miR-23b, miR-497, miR-26a, and miR-20b, or by suppression of miR-182, miR-181c, miR-223, miR-155, and miR873. Further studies are warranted on determining more fully miRNA profiles in blood plasma and urine exosomes of experimental autoimmune encephalomyelitis animals since they could serve as biomarkers of asymptomatic multiple sclerosis and disease course. Additionally, studies should be performed with male mice of a similar age, and with aged male and female mice.},
doi = {10.4103/1673-5374.280307},
journal = {Neural Regeneration Research},
number = 10,
volume = 15,
place = {United States},
year = {Fri Apr 03 00:00:00 EDT 2020},
month = {Fri Apr 03 00:00:00 EDT 2020}
}

Works referenced in this record:

MicroRNAs as modulators and biomarkers of inflammatory and neuropathic pain conditions
journal, November 2014


MicroRNAs Modulate Hematopoietic Lineage Differentiation
journal, January 2004


Immunopathology of multiple sclerosis
journal, August 2015

  • Dendrou, Calliope A.; Fugger, Lars; Friese, Manuel A.
  • Nature Reviews Immunology, Vol. 15, Issue 9
  • DOI: 10.1038/nri3871

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis
journal, February 2008


MicroRNA-181 Variants Regulate T Cell Phenotype in the Context of Autoimmune Neuroinflammation
journal, July 2017


MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
journal, July 2007


The Potential for microRNA Therapeutics and Clinical Research
journal, May 2019


Sex and gender issues in multiple sclerosis
journal, May 2013

  • Harbo, Hanne F.; Gold, Ralf; Tintoré, Mar
  • Therapeutic Advances in Neurological Disorders, Vol. 6, Issue 4
  • DOI: 10.1177/1756285613488434

Multiple sclerosis
journal, March 2004


Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation
journal, October 2011


Inflammatory demyelination induces glia alterations and ganglion cell loss in the retina of an experimental autoimmune encephalomyelitis model
journal, October 2013

  • Horstmann, Lioba; Schmid, Heiko; Heinen, André P.
  • Journal of Neuroinflammation, Vol. 10, Issue 1
  • DOI: 10.1186/1742-2094-10-120

Increased expression of microRNA-15a and microRNA-15b in skeletal muscle from adult offspring of women with diabetes in pregnancy
journal, March 2018

  • Houshmand-Oeregaard, Azadeh; Schrölkamp, Maren; Kelstrup, Louise
  • Human Molecular Genetics, Vol. 27, Issue 10
  • DOI: 10.1093/hmg/ddy085

Biomarkers in multiple sclerosis
journal, November 2015


Neuronal microRNA regulation in Experimental Autoimmune Encephalomyelitis
journal, September 2018


MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability
journal, May 2006


CCAR1 5′ UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance
journal, March 2016

  • Li, Gaopeng; Wu, Xiaoli; Qian, Wenchang
  • Cell Research, Vol. 26, Issue 6
  • DOI: 10.1038/cr.2016.32

Dysregulation of microRNAs in autoimmune diseases: Pathogenesis, biomarkers and potential therapeutic targets
journal, August 2018


Expression, Regulation and Function of MicroRNAs in Multiple Sclerosis
journal, January 2014

  • Ma, Xinting; Zhou, Juhua; Zhong, Yin
  • International Journal of Medical Sciences, Vol. 11, Issue 8
  • DOI: 10.7150/ijms.8647

Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014–2019
journal, January 2020


MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression
journal, January 2020


MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis
journal, August 2019

  • Morquette, Barbara; Juźwik, Camille A.; Drake, Sienna S.
  • Brain, Vol. 142, Issue 10
  • DOI: 10.1093/brain/awz245

JC-virus seroconversion in multiple sclerosis patients receiving natalizumab
journal, September 2013

  • Outteryck, Olivier; Zéphir, Hélène; Salleron, Julia
  • Multiple Sclerosis Journal, Vol. 20, Issue 7
  • DOI: 10.1177/1352458513505353

Neuropathobiology of multiple sclerosis
journal, February 2005


Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy
journal, October 2014

  • Plavina, Tatiana; Subramanyam, Meena; Bloomgren, Gary
  • Annals of Neurology, Vol. 76, Issue 6
  • DOI: 10.1002/ana.24286

MicroRNA-92a Drives Th1 Responses in the Experimental Autoimmune Encephalomyelitis
journal, November 2018


Cytokine Targeting by miRNAs in Autoimmune Diseases
journal, January 2019


Micro RNA 223 promotes pathogenic T‐cell development and autoimmune inflammation in central nervous system in mice
journal, June 2016

  • Satoorian, Tiffany; Li, Bo; Tang, Xiaolei
  • Immunology, Vol. 148, Issue 4
  • DOI: 10.1111/imm.12611

MicroRNA-150 targets PU.1 and regulates macrophage differentiation and function in experimental autoimmune encephalomyelitis
journal, October 2018


IL-17-triggered downregulation of miR-497 results in high HIF-1α expression and consequent IL-1β and IL-6 production by astrocytes in EAE mice
journal, May 2017

  • Shan, Kai; Pang, Rongrong; Zhao, Chenhui
  • Cellular & Molecular Immunology, Vol. 14, Issue 11
  • DOI: 10.1038/cmi.2017.12

The utility of cerebrospinal fluid analysis in patients with multiple sclerosis
journal, March 2013

  • Stangel, Martin; Fredrikson, Sten; Meinl, Edgar
  • Nature Reviews Neurology, Vol. 9, Issue 5
  • DOI: 10.1038/nrneurol.2013.41

MicroRNA-142 regulates inflammation and T cell differentiation in an animal model of multiple sclerosis
journal, March 2017

  • Talebi, Farideh; Ghorbani, Samira; Chan, Wing Fuk
  • Journal of Neuroinflammation, Vol. 14, Issue 1
  • DOI: 10.1186/s12974-017-0832-7

Tuftsin Combines With Remyelinating Therapy and Improves Outcomes in Models of CNS Demyelinating Disease
journal, November 2018

  • Thompson, Kaitlyn K.; Nissen, Jillian C.; Pretory, Amanda
  • Frontiers in Immunology, Vol. 9
  • DOI: 10.3389/fimmu.2018.02784

Epidemiology and treatment of multiple sclerosis in elderly populations
journal, April 2019

  • Vaughn, Caila B.; Jakimovski, Dejan; Kavak, Katelyn S.
  • Nature Reviews Neurology, Vol. 15, Issue 6
  • DOI: 10.1038/s41582-019-0183-3

The miRNA Expression Profile of Experimental Autoimmune Encephalomyelitis Reveals Novel Potential Disease Biomarkers
journal, December 2018

  • Venkatesha, Shivaprasad; Dudics, Steven; Song, Yang
  • International Journal of Molecular Sciences, Vol. 19, Issue 12
  • DOI: 10.3390/ijms19123990

MicroRNA 182 promotes T helper 1 cell by repressing hypoxia induced factor 1 alpha in experimental autoimmune encephalomyelitis
journal, September 2019

  • Wan, Cong; Bi, Wuchun; Lin, Peng
  • European Journal of Immunology, Vol. 49, Issue 12
  • DOI: 10.1002/eji.201948111

Brain Endothelial miR-146a Negatively Modulates T-Cell Adhesion through Repressing Multiple Targets to Inhibit NF-κB Activation
journal, March 2015

  • Wu, Dongsheng; Cerutti, Camilla; Lopez-Ramirez, Miguel A.
  • Journal of Cerebral Blood Flow & Metabolism, Vol. 35, Issue 3
  • DOI: 10.1038/jcbfm.2014.207

Axon Loss in the Spinal Cord Determines Permanent Neurological Disability in an Animal Model of Multiple Sclerosis
journal, January 2002

  • Wujek, Jerome R.; Bjartmar, Carl; Richer, Edward
  • Journal of Neuropathology & Experimental Neurology, Vol. 61, Issue 1
  • DOI: 10.1093/jnen/61.1.23

miR26a Modulates Th17/Treg Balance in the EAE Model of Multiple Sclerosis by Targeting IL6
journal, November 2014


miR-23b Suppresses Leukocyte Migration and Pathogenesis of Experimental Autoimmune Encephalomyelitis by Targeting CCL7
journal, February 2018


MicroRNA-181c promotes Th17 cell differentiation and mediates experimental autoimmune encephalomyelitis
journal, May 2018


miR-20b Suppresses Th17 Differentiation and the Pathogenesis of Experimental Autoimmune Encephalomyelitis by Targeting RORγt and STAT3
journal, May 2014


Clinical-Magnetic Resonance Imaging Correlations in Multiple Sclerosis
journal, October 2005